Avanza Fonder AB Increases Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Avanza Fonder AB raised its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 17.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,049 shares of the company’s stock after purchasing an additional 444 shares during the period. Avanza Fonder AB’s holdings in Janux Therapeutics were worth $86,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. increased its stake in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. bought a new stake in Janux Therapeutics in the fourth quarter valued at $59,000. GAMMA Investing LLC increased its position in Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after purchasing an additional 1,574 shares during the period. Meeder Asset Management Inc. bought a new position in Janux Therapeutics in the 4th quarter worth $159,000. Finally, Tower Research Capital LLC TRC raised its holdings in Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock worth $205,000 after purchasing an additional 3,436 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on JANX shares. Wedbush reiterated an “outperform” rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank cut their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $25.56 on Friday. The firm has a market capitalization of $1.51 billion, a P/E ratio of -21.85 and a beta of 2.96. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The company’s 50-day simple moving average is $27.00 and its 200 day simple moving average is $37.20.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.10% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.